Other substances

Danoprevir

A hepatitis C virus protease inhibitor.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Danoprevir is an experimental anti-hepatitis C virus drug (DrugBank).

Danoprevir on PubChem
Danoprevir on Wikipedia

CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients Preprint	Patients		in combination with ritonavir	Mar/24/2020
Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease 3CLpro Small molecule In silico	in silico	1.77	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Dec/11/2020

AI-suggested references

Link	Publication date
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.	Mar/03/2022
Finding a prospective dual-target drug for the treatment of coronavirus disease by theoretical study.	Sep/13/2021
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.	Aug/18/2020
Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports	Jul/20/2020
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Feb/25/2021
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients	Aug/02/2021
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches	Apr/07/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04291729	Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	Phase 4	Feb/17/2020	Mar/19/2020
Alternative id - ASC-CTP-NC-01 Interventions - Drug: Ganovo+ritonavir+/-Interferon nebulization Study type - Interventional Study results - No Results Available Locations - The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 11 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Rate of composite adverse outcomes\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requiring supplemental oxygen\|Rate of undetectable New coronavirus pathogen nucleic acid\|Rate of mechanical ventilation\|Rate of ICU admission\|Rate of serious adverse event
NCT04345276	Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection	Completed	Phase 4	Mar/18/2020	Apr/15/2020
Alternative id - ASC-CTP-HS-01 Interventions - Drug: Danoprevir+Ritonavir Study type - Interventional Study results - No Results Available Locations - Huoshenshan Hostipal, Wuhan, Hubei, China Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 10 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Rate of composite adverse outcomes\|Time to recovery\|Rate of no fever\|Rate of no cough\|Rate of no dyspnea\|Rate of no requiring supplemental oxygen\|Rate of undetectable New coronavirus pathogen nucleic acid\|Rate of mechanical ventilation\|Rate of ICU admission\|Rate of serious adverse event

Export (.csv)